Rapport Therapeutics, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Abraham N. Ceesay
- Full Time Employees
- 69
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1325 Boylston Street Boston DE United States of America
- IPO Date
- Jun 7, 2024
- CIK
- 0002012593
- Website
- rapportrx.com
- Similar Companies
- Business
- Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biopharmaceutical company focused on discovering and developing precision small molecule medicines targeting central nervous system (CNS) disorders through its proprietary RAP technology platform. The company advances a pipeline including lead candidate RAP-219, a TARPγ8-selective AMPAR inhibitor for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain; RAP-199, a differentiated TARPγ8-targeted molecule; and discovery-stage nicotinic acetylcholine receptor (nAChR) programs comprising α6 nAChR modulators for chronic pain and α9α10 nAChR modulators for hearing disorders. Founded in 2022 and headquartered in Boston, Massachusetts, with additional operations in San Diego, California, Rapport targets patients with neurological conditions underserved by broad-acting therapies. Recent developments include positive topline results from a Phase 2a trial of RAP-219 in focal onset seizures announced in September 2025, demonstrating a 78% median seizure reduction; ongoing Phase 2 enrollment in bipolar mania with results expected in first-half 2027; plans for an FDA end-of-Phase 2 meeting by year-end 2025 and two Phase 3 pivotal trials in focal onset seizures starting third-quarter 2026; and approximately $269 million in net proceeds from a recent public offering, extending cash runway into second-half 2029. The company, formerly Precision Neuroscience NewCo, Inc., went public on Nasdaq in June 2024 following a $150 million Series B financing in 2023 led by Cormorant Asset Management.
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Modalités de mise à disposition du rapport financier annuel 2025
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Communiqué de mise à disposition du rapport financier annuel 2025
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Target Price at $51.40
Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
CRCAM Toulouse 31 - Rapport financier annuel 2025
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP
Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Brokerages Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) PT at $47.00